Abstract
Patients with active malignancy frequently require anticoagulation for a variety of indications, including thrombosis, atrial fibrillation, or mechanical heart valves. Cancer-associated thrombosis is associated with significant morbidity and mortality and necessitates extended anticoagulation for the duration of active cancer. However, the bleeding risk in this population is heightened due to tumor-related factors such as cancer site (eg, primary or secondary brain tumors), invasive procedures (surgeries, biopsies, etc), and side effects of cancer-directed therapies such as thrombocytopenia. Moreover, there are specific bleeding risk factors unique to individual patients, including medications and preexisting bleeding disorders. Together, these factors substantially increase the likelihood of bleeding events in patients receiving anticoagulation for cancer-associated thrombosis. In this review, we outline the various risk factors contributing to increased bleeding risk in patients with cancer and thrombosis and describe management strategies to ensure safe anticoagulation aimed at minimizing thrombotic complications and hemorrhagic risk.
References
1.
Trousseau
A.
Phlegmasia alba dolens
.
(2nd)
ed. Vol 3
. Clinique medicule de l'Hotel-Dieu de Paris
; 1865
:94
.2.
Agnelli
G.
Venous thromboembolism and cancer: a two-way clinical association
. Thromb Haemost
. 1997
;78
(1
):117
-120
.3.
Khorana
AA
, Mackman
N
, Falanga
A
, et al. Cancer-associated venous thromboembolism
. Nat Rev Dis Primers
. 2022
;8
(1
):11
.4.
Agnelli
G
, Becattini
C
, Meyer
G
, et al; Caravaggio Investigators
. Apixaban for the treatment of venous thromboembolism associated with cancer
. N Engl J Med
. 2020
;382
(17
):1599
-1607
.5.
Lyman
GH
, Carrier
M
, Ay
C
, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
. Blood Adv
. 2021
;5
(4
):927
-974
.6.
Angelini
DE
, Radivoyevitch
T
, McCrae
KR
, Khorana
AA
. Bleeding incidence and risk factors among cancer patients treated with anticoagulation
. Am J Hematol
. 2019
;94
(7
):780
-785
.7.
Young
AM
, Marshall
A
, Thirlwall
J
, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)
. J Clin Oncol
. 2018
;36
(20
):2017
-2023
.8.
Ageno
W
, Vedovati
MC
, Cohen
A
, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study
. Thromb Haemost
. 2021
;121
(5
):616
-624
.9.
Houghton
DE
, Vlazny
DT
, Casanegra
AI
, et al. Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism
. Mayo Clin Proc
. 2021
;96
(11
):2793
-2805
.10.
Englisch
C
, Moik
F
, Steiner
D
, et al. Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study
. Blood
. 2024
;144
(22
):2349
-2359
.11.
Berry
J
, Patell
R
, Zwicker
JI
. The bridging conundrum: perioperative management of direct oral anticoagulants for venous thromboembolism
. J Thromb Haemost
. 2023
;21
(4
):780
-786
.12.
Douketis
JD
, Spyropoulos
AC
, Kaatz
S
, et al; BRIDGE Investigators
. Perioperative bridging anticoagulation in patients with atrial fibrillation
. N Engl J Med
. 2015
;373
(9
):823
-833
.13.
Douketis
JD
, Spyropoulos
AC
, Duncan
J
, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant
. JAMA Intern Med
. 2019
;179
(11
):1469
-1478
.14.
Shaw
JR
, Li
N
, Abdulrehman
J
, et al. Periprocedural management of direct oral anticoagulants in patients with atrial fibrillation and active cancer
. J Thromb Haemost
. 2024
;22
(3
):727
-737
.15.
Streiff
MB
, Agnelli
G
, Connors
JM
, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism
. J Thromb Thrombolysis
. 2016
;41
(1
):32
-67
.16.
Duffett
L
, Carrier
M.
Inferior vena cava filters
. J Thromb Haemost
. 2017
; 15
(1
):3
-12
.17.
Kurzyna
P
, Banaszkiewicz
M
, Florczyk
M
, et al. Safety and outcomes of inferior vena cava filter placement in oncology patients: a single-centre experience
. Cancers (Basel)
. 2024
;16
(8
):1562
.18.
De Crem
N
, Peerlinck
K
, Vanassche
T
, et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists
. Thromb Res
. 2015
;136
(4
):749
-753
.19.
James
AH
. Heavy menstrual bleeding: work-up and management
. Hematology Am Soc Hematol Educ Program
. 2016
;2016
(1
):236
-242
.20.
Bannow
BS
. Management of heavy menstrual bleeding on anticoagulation
. Hematology Am Soc Hematol Educ Program
. 2020
;2020
(1
):533
-537
.21.
Hermans
C.
Thrombosis and hemophilia: little more evidence, much more guidance
. Hemasphere
. 2023
;7
(6
):e918
.22.
James
AH
. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders
. Haemophilia
. 2005
;11
(4
): 295
-307
.23.
Rodeghiero
F
, Tosetto
A
, Abshire
T
, et al; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group
. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders
. J Thromb Haemost
. 2010
;8
(9
):2063
-2065
.24.
Bryk
AH
, Piróg
M
, Plens
K
, Undas
A.
Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism
. Vascul Pharmacol
. 2016
;87
:242
-247
.25.
Ortel
TL
, Neumann
I
, Ageno
W
, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
. Blood Adv
. 2020
; 4
(19
):4693
-4738
.26.
Agnelli
G
, Buller
HR
, Cohen
A
, et al; AMPLIFY-EXT Investigators
. Apixaban for extended treatment of venous thromboembolism
. N Engl J Med
. 2013
;368
(8
):699
-708
.27.
Weitz
JI
, Lensing
AWA
, Prins
MH
, et al; EINSTEIN CHOICE Investigators
. Rivaroxaban or aspirin for extended treatment of venous thromboembolism
. N Engl J Med
. 2017
;376
(13
):1211
-1222
.28.
Mahé
I
, Carrier
M
, Mayeur
D
, et al; API-CAT Investigators
. Extended reduced-dose apixaban for cancer-associated venous thromboembolism
. N Engl J Med
. 2025
;392
(14
):1363
-1373
.29.
Pérez-Jacoiste
Asín MA
, Blanco Molina
Á
, Gómez-Cuervo
C
, et al; RIETE Investigators
. Venous thromboembolism in women with hormone-dependent breast cancer. To continue or discontinue hormonal treatment? Insights from the RIETE registry
. Thromb Res
. 2024
;241
:109087
.30.
Chornenki
NLJ
, Um
KJ
, Mendoza
PA
, et al. Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: a systematic review and meta-analysis
. Thromb Res
. 2019
;179
:81
-86
.31.
Franchini
M
, Di Perna
C
, Santoro
C
, et al; Italian Association of Haemophilia Centres
. Cancers in patients with von Willebrand disease: a survey from the Italian Association of Haemophilia Centres
. Semin Thromb Hemost
. 2016
;42
(1
):36
-41
.32.
Biron-Andreani
C
, de Moerloose
P
, D'oiron
R
, Chambost
H
, Schved
J-F
, Hermans
C.
Cancer detection and management in patients with haemophilia: a retrospective European multicentre study
. Haemophilia
. 2014
;20
(1
): 78
-82
.33.
Shapiro
AD
, Hardesty
BM
, Peyvandi
F
, Iorio
A.
Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: a scoping review
. Res Pract Thromb Haemost
. 2023
;7
(1
):100007
.34.
Verhagen
MJA
, Valke
LLFG
, Schols
SEM
. Thrombin generation for monitoring hemostatic therapy in hemophilia A: a narrative review
. J Thromb Haemost
. 2022
;20
(4
):794
-805
.35.
de Koning
MLY
, Fischer
K
, de Laat
B
, Huisman
A
, Ninivaggi
M
, Schutgens
REG
. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists
. J Thromb Haemost
. 2017
;15
(5
):868
-875
.36.
Gilmore
R
, Harmon
S
, Gannon
C
, Byrne
M
, O'Donnell
JS
, Jenkins
PV
. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy
. Haemophilia
. 2010
;16
(4
):671
-674
.37.
Schutgens
REG
, Jimenez-Yuste
V
, Escobar
M
, et al. Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
. Hemasphere
. 2023
;7
(6
):e900
.38.
Gill
JC
, Mannucci
PM
. Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery
. Haemophilia
. 2014
;20
(6
):e404
-e406
.39.
Cushman
M.
Epidemiology and risk factors for venous thrombosis
. Semin Hematol
. 2007
;44
(2
):62
-69
.40.
Cho
H
, Yoo
KY
, Shin
J-Y
, Lee
E-K
, Choi
B.
Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration adverse event reporting system data
. J Thromb Haemost
. 2024
;22
(6
):1640
-1648
.41.
Young
G
, Kavakli
K
, Klamroth
R
, et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
. Blood
. 2025
;145
(25
):2966
-2977
.42.
Chowdary
P
, Angchaisuksiri
P
, Apte
S
, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial
. Lancet Haematol
. 2024
;11
(12
):e891
-e904
.43.
Verso
M
, Agnelli
G.
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients
. J Clin Oncol
. 2003
;21
(19
):3665
-3675
.44.
Björklund
J
, Rautiola
J
, Zelic
R
, et al. Risk of venous thromboembolic events after surgery for cancer
. JAMA Netw Open
. 2024
;7
(2
):e2354352
.45.
Bennett
CL
, Angelotta
C
, Yarnold
PR
, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer
. JAMA
. 2006
; 296
(21
):2558
-2560
.46.
Vedovati
MC
, Giustozzi
M
, Munoz
A
, et al. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism
. Eur J Intern Med
. 2023
;112
:29
-36
.47.
Giustozzi
M
, Proietti
G
, Becattini
C
, Roila
F
, Agnelli
G
, Mandalà
M.
ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis
. Blood Adv
. 2022
;6
(16
):4873
-4883
.48.
Srivastava
A
, Santagostino
E
, Dougall
A
, et al; WFH guidelines for the management of hemophilia panelists and co-authors
. WFH guidelines for the management of hemophilia
,
(3rd)
edition. Haemophilia
. 2020
;26
(suppl 6
): 1
-158
.49.
Martin
K
, Key
NS
. How I treat patients with inherited bleeding disorders who need anticoagulant therapy
. Blood
. 2016
;128
(2
):178
-184
.Copyright © 2025 by The American Society of Hematology
2025
You do not currently have access to this content.
